FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030374413> ?p ?o ?g. }

• W3030374413 endingPage "689.e5" @default.
• W3030374413 startingPage "677" @default.
• W3030374413 abstract "Purpose Gabapentinoids are commonly prescribed for the treatment of neuropathic pain but are not recommended for the primary treatment of carpal tunnel syndrome (CTS). We sought (1) to investigate the preoperative use of gabapentinoids for the treatment of CTS and (2) to determine whether preoperative exposure is associated with persistent gabapentinoid and opioid use after carpal tunnel release. Methods We performed a retrospective cohort study using IBM MarketScan Research Databases (2010–2017) of patients who did not fill a gabapentinoid or opioid prescription within 3 months of a new CTS diagnosis undergoing surgical release. Our primary outcomes included preoperative gabapentinoid prescription fills associated with CTS and persistent prescription fills of gabapentinoids and opioids at 91 to 180 days after surgery. Multivariable logistic regression models were used to evaluate the association between patient-level factors and persistent gabapentinoid and opioid use. Results Of the 56,593 patients without a previous gabapentinoid or opioid prescription prior to diagnosis of CTS, 3,474 patients (6%) filled a gabapentinoid prescription before carpal tunnel release. Overall, 835 patients (24% of the preoperative users) continued to fill gabapentinoid prescriptions at 91 to 180 days after surgery. Of the preoperative gabapentinoid users, 20% (702 patients) continued to fill opioid prescriptions at 91 to 80 days after release. After adjusting for patient characteristics, preoperative gabapentinoid use was associated with increased odds of persistent postoperative gabapentinoid use (preoperative gabapentinoid, 22% adjusted probability; 95% confidence interval [95% CI], 20.3%–23.0%, no preoperative gabapentinoid use, 1%; 95% CI, 1.2%–1.4%) and persistent postoperative opioid use (preoperative gabapentinoid, 18% adjusted probability; 95% CI, 17%–20%), no preoperative gabapentinoid, 9%; 95% CI, 8.6%–9.1%). Conclusions Despite a lack of evidence to support the use of gabapentinoids for CTS, 6% of patients are prescribed a gabapentinoid prior to surgery, and prolonged use is common. Given the effectiveness of surgical release and the risks associated with gabapentinoids, greater attention is needed to ensure that gabapentinoids are prescribed appropriately, avoided when possible, and stopped after surgery. Type of study/level of evidence Prognostic II. Gabapentinoids are commonly prescribed for the treatment of neuropathic pain but are not recommended for the primary treatment of carpal tunnel syndrome (CTS). We sought (1) to investigate the preoperative use of gabapentinoids for the treatment of CTS and (2) to determine whether preoperative exposure is associated with persistent gabapentinoid and opioid use after carpal tunnel release. We performed a retrospective cohort study using IBM MarketScan Research Databases (2010–2017) of patients who did not fill a gabapentinoid or opioid prescription within 3 months of a new CTS diagnosis undergoing surgical release. Our primary outcomes included preoperative gabapentinoid prescription fills associated with CTS and persistent prescription fills of gabapentinoids and opioids at 91 to 180 days after surgery. Multivariable logistic regression models were used to evaluate the association between patient-level factors and persistent gabapentinoid and opioid use. Of the 56,593 patients without a previous gabapentinoid or opioid prescription prior to diagnosis of CTS, 3,474 patients (6%) filled a gabapentinoid prescription before carpal tunnel release. Overall, 835 patients (24% of the preoperative users) continued to fill gabapentinoid prescriptions at 91 to 180 days after surgery. Of the preoperative gabapentinoid users, 20% (702 patients) continued to fill opioid prescriptions at 91 to 80 days after release. After adjusting for patient characteristics, preoperative gabapentinoid use was associated with increased odds of persistent postoperative gabapentinoid use (preoperative gabapentinoid, 22% adjusted probability; 95% confidence interval [95% CI], 20.3%–23.0%, no preoperative gabapentinoid use, 1%; 95% CI, 1.2%–1.4%) and persistent postoperative opioid use (preoperative gabapentinoid, 18% adjusted probability; 95% CI, 17%–20%), no preoperative gabapentinoid, 9%; 95% CI, 8.6%–9.1%). Despite a lack of evidence to support the use of gabapentinoids for CTS, 6% of patients are prescribed a gabapentinoid prior to surgery, and prolonged use is common. Given the effectiveness of surgical release and the risks associated with gabapentinoids, greater attention is needed to ensure that gabapentinoids are prescribed appropriately, avoided when possible, and stopped after surgery." @default.
• W3030374413 created "2020-06-05" @default.
• W3030374413 creator A5030337104 @default.
• W3030374413 creator A5062148006 @default.
• W3030374413 creator A5065418957 @default.
• W3030374413 creator A5065945106 @default.
• W3030374413 creator A5073325161 @default.
• W3030374413 creator A5079665015 @default.
• W3030374413 creator A5080061468 @default.
• W3030374413 creator A5088072335 @default.
• W3030374413 date "2020-08-01" @default.
• W3030374413 modified "2023-10-18" @default.
• W3030374413 title "Inappropriate Preoperative Gabapentinoid Use Among Patients With Carpal Tunnel Syndrome" @default.
• W3030374413 cites W1521286422 @default.
• W3030374413 cites W1535216622 @default.
• W3030374413 cites W1547787343 @default.
• W3030374413 cites W1979366562 @default.
• W3030374413 cites W1998240591 @default.
• W3030374413 cites W2000445173 @default.
• W3030374413 cites W2014670473 @default.
• W3030374413 cites W2027343175 @default.
• W3030374413 cites W2062262109 @default.
• W3030374413 cites W2090920511 @default.
• W3030374413 cites W2100082403 @default.
• W3030374413 cites W2129168200 @default.
• W3030374413 cites W2137549673 @default.
• W3030374413 cites W2273108584 @default.
• W3030374413 cites W2296986887 @default.
• W3030374413 cites W2335347226 @default.
• W3030374413 cites W2524590873 @default.
• W3030374413 cites W2583970354 @default.
• W3030374413 cites W2607168684 @default.
• W3030374413 cites W2610104393 @default.
• W3030374413 cites W2618114875 @default.
• W3030374413 cites W2740244424 @default.
• W3030374413 cites W2760847338 @default.
• W3030374413 cites W2763928864 @default.
• W3030374413 cites W2773261190 @default.
• W3030374413 cites W2782300316 @default.
• W3030374413 cites W2796678187 @default.
• W3030374413 cites W2808824431 @default.
• W3030374413 cites W2885125510 @default.
• W3030374413 cites W2924513576 @default.
• W3030374413 cites W2989049872 @default.
• W3030374413 doi "https://doi.org/10.1016/j.jhsa.2020.04.011" @default.
• W3030374413 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7453721" @default.
• W3030374413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32487365" @default.
• W3030374413 hasPublicationYear "2020" @default.
• W3030374413 type Work @default.
• W3030374413 sameAs 3030374413 @default.
• W3030374413 citedByCount "7" @default.
• W3030374413 countsByYear W30303744132022 @default.
• W3030374413 countsByYear W30303744132023 @default.
• W3030374413 crossrefType "journal-article" @default.
• W3030374413 hasAuthorship W3030374413A5030337104 @default.
• W3030374413 hasAuthorship W3030374413A5062148006 @default.
• W3030374413 hasAuthorship W3030374413A5065418957 @default.
• W3030374413 hasAuthorship W3030374413A5065945106 @default.
• W3030374413 hasAuthorship W3030374413A5073325161 @default.
• W3030374413 hasAuthorship W3030374413A5079665015 @default.
• W3030374413 hasAuthorship W3030374413A5080061468 @default.
• W3030374413 hasAuthorship W3030374413A5088072335 @default.
• W3030374413 hasBestOaLocation W30303744132 @default.
• W3030374413 hasConcept C126322002 @default.
• W3030374413 hasConcept C141071460 @default.
• W3030374413 hasConcept C142724271 @default.
• W3030374413 hasConcept C151956035 @default.
• W3030374413 hasConcept C156957248 @default.
• W3030374413 hasConcept C167135981 @default.
• W3030374413 hasConcept C170493617 @default.
• W3030374413 hasConcept C201903717 @default.
• W3030374413 hasConcept C204787440 @default.
• W3030374413 hasConcept C2426938 @default.
• W3030374413 hasConcept C2776468701 @default.
• W3030374413 hasConcept C2776608144 @default.
• W3030374413 hasConcept C2777831278 @default.
• W3030374413 hasConcept C2777832143 @default.
• W3030374413 hasConcept C2779746960 @default.
• W3030374413 hasConcept C2781063702 @default.
• W3030374413 hasConcept C2910872340 @default.
• W3030374413 hasConcept C42219234 @default.
• W3030374413 hasConcept C44249647 @default.
• W3030374413 hasConcept C71924100 @default.
• W3030374413 hasConcept C72563966 @default.
• W3030374413 hasConcept C98274493 @default.
• W3030374413 hasConceptScore W3030374413C126322002 @default.
• W3030374413 hasConceptScore W3030374413C141071460 @default.
• W3030374413 hasConceptScore W3030374413C142724271 @default.
• W3030374413 hasConceptScore W3030374413C151956035 @default.
• W3030374413 hasConceptScore W3030374413C156957248 @default.
• W3030374413 hasConceptScore W3030374413C167135981 @default.
• W3030374413 hasConceptScore W3030374413C170493617 @default.
• W3030374413 hasConceptScore W3030374413C201903717 @default.
• W3030374413 hasConceptScore W3030374413C204787440 @default.
• W3030374413 hasConceptScore W3030374413C2426938 @default.
• W3030374413 hasConceptScore W3030374413C2776468701 @default.
• W3030374413 hasConceptScore W3030374413C2776608144 @default.
• W3030374413 hasConceptScore W3030374413C2777831278 @default.

• next